Julia Bonavitacola

Countries located in sub-Saharan Africa would be most affected by all funding cuts to the international HIV response.

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish efficacy, according to the FDA.

Both refractive and corneal astigmatism saw an increase in prevalence in children after the COVID-19 pandemic, with corneal changes potentially playing a part.

Annie Antar, MD, PhD, spoke about how long viral clearance could be an indicator of long COVID, but more research would need to be done to confirm this.

The Trump administration has expressed interest in eliminating or changing the Division of HIV Prevention in the CDC, which could introduce gaps in addressing the HIV epidemic.

While the prevention program worked as intended in White American youth, Black youth participants did not have success with the same program.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The extension of the emergency declaration, originally set to expire on March 21, continues to allocate funding to addressing the opioid crisis.

The HIV prevention division could be rolled into another department of the HHS as soon as the end of the week.

Annie Antar, MD, PhD, discusses how patients with HIV can have different and longer-lasting symptoms of COVID-19.

Michelle Hessen, OD, discusses how cyclosporine ophthalmic solution 0.09% is safe to use in patients with dry eye, as well as where future research should turn.

Annie Antar, MD, PhD, discusses the association between the symptoms of long COVID and HIV status.

The Conference on Retroviruses and Opportunistic Infections 2025 (CROI) featured multiple sessions that focused on breaking research and treatments.

The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a combination antiretroviral therapy (ART) in its long-acting injectable form.

Michelle Hessen, OD, spoke about the results of a new study evaluating the efficacy of cyclosporine ophthalmic solution 0.09% in patients with dry eye.

The topical treatment had no significant effect on total or central corneal fluorescence staining score.

Patients in Washington, DC, and San Francisco had minimal early uptake and adherence to doxycycline postexposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and Opportunistic Infections 2025.

When patients switched to either fostemsavir or the combination of dolutegravir/lamivudine (DTG/3TC), suppression was maintained in most patients.

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but requires methods of improving adherence to follow-up.

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, that has been made in the fight against the HIV pandemic given the current political climate.

Physicians are more likely to order respiratory pathogen testing since the COVID-19 pandemic, affecting testing rates and costs.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

This year’s Conference on Retroviruses and Opportunistic Infections (CROI) features several sessions discussing prevention and treatment of viral infections like HIV and COVID-19.

Information on health equity was removed by the federal government for both the Children’s Health Insurance Program and Medicaid.

Clinical trials for diabetic macular edema (DME) continue to see disparities in enrollment.

Attendees and experts from the Southeastern Educational Congress of Optometry (SECO) 2025 meeting highlight research and sessions they will take away.

A survey of HIV health care providers in the US revealed the various approaches that providers took for prescribing antiretroviral therapy (ART).

Brianna Rhue, OD, FAAO, discusses the pitfalls of myopia treatment and accessibility of that treatment.